New AusPARs
April 15, 2016
THE TGA has added two
Australian Public Assessment
Reports (AusPARs): follitropin alfa
(rch) (Bemfola, Afolia from Finox
Biotech Australia) for hormone
management in specific patients
and eltrombopag (Revolade by
Novartis) for certain patients with
aplastic anaemia.
MEA NWHILE the TGA’s Advisory
Committee on Prescription
Medicines has summarised
the therapeutic goods referred
for advice revealing a list of 15
products of which seven are new
chemical entities, including an
inactivated influenza virus vaccine
(surface antigens).
Six products: anakinra,
etanercept, regorafenib, rifaximin,
apixaban and adalimumab had
extensions to their indications,
while rituximab recorded a major
variation relating to its dosing.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Apr 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Apr 16